Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.50 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16121247 | 1.00 | SMARCA2 (0.50) | SMARCA2SMARCA4CYP17A1PRKCIATR | |
| SCHEMBL21614653 | 0.91 | SMARCA2 (0.60) | SMARCA2SMARCA4CYP17A1PRKCIATR | |
| SCHEMBL29099947 | 0.84 | MAP4K4 (0.44) | SMARCA2SMARCA4CYP17A1PRKCIATR | |
| SCHEMBL28400383 | 0.83 | ATR (0.45) | SMARCA2SMARCA4CYP17A1PRKCIATR | |
| SCHEMBL16369790 | 0.82 | SMARCA2 (0.51) | SMARCA2SMARCA4PRKCIRAF1BRAF | |
| SCHEMBL16055308 | 0.81 | SMARCA2 (0.57) | SMARCA2SMARCA4CYP17A1ATRCA12 | |
| SCHEMBL1501665 | 0.81 | SMARCA2 (0.57) | SMARCA2SMARCA4CYP17A1ATRCA12 | |
| SCHEMBL30293080 | 0.81 | SMARCA2 (0.57) | SMARCA2SMARCA4CYP17A1ATRCA12 | |
| SCHEMBL2596875 | 0.79 | AR (0.56) | SMARCA2SMARCA4CYP17A1ATRCA12 | |
| SCHEMBL29383469 | 0.79 | AR (0.56) | SMARCA2SMARCA4CYP17A1ATRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12433895-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240335448-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | PHARMARESROUCES (SHANGHAI) CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-12-19 | — | — | US | disclosed |
| CN-117120427-A | MALT1 inhibitor and preparation method and application thereof | 上海拓界生物医药科技有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20220354856-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12433895-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | SMARCA2 1910/4885SMARCA4 2048/4885CYP17A1 2927/4885 |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | SMARCA2 1910/4885SMARCA4 2048/4885CYP17A1 2927/4885 |
| US-20240335448-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | SMARCA2 1910/4885SMARCA4 2048/4885CYP17A1 2927/4885 |
| US-20220354856-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | SMARCA2 1910/4885SMARCA4 2048/4885CYP17A1 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.